收费全文 | 13625篇 |
免费 | 746篇 |
国内免费 | 65篇 |
耳鼻咽喉 | 231篇 |
儿科学 | 378篇 |
妇产科学 | 255篇 |
基础医学 | 1618篇 |
口腔科学 | 436篇 |
临床医学 | 1005篇 |
内科学 | 3698篇 |
皮肤病学 | 269篇 |
神经病学 | 1251篇 |
特种医学 | 476篇 |
外科学 | 2018篇 |
综合类 | 55篇 |
一般理论 | 8篇 |
预防医学 | 905篇 |
眼科学 | 280篇 |
药学 | 664篇 |
中国医学 | 31篇 |
肿瘤学 | 858篇 |
2024年 | 15篇 |
2023年 | 99篇 |
2022年 | 282篇 |
2021年 | 538篇 |
2020年 | 290篇 |
2019年 | 421篇 |
2018年 | 565篇 |
2017年 | 345篇 |
2016年 | 371篇 |
2015年 | 427篇 |
2014年 | 584篇 |
2013年 | 666篇 |
2012年 | 1098篇 |
2011年 | 1077篇 |
2010年 | 605篇 |
2009年 | 549篇 |
2008年 | 914篇 |
2007年 | 882篇 |
2006年 | 773篇 |
2005年 | 836篇 |
2004年 | 706篇 |
2003年 | 584篇 |
2002年 | 542篇 |
2001年 | 129篇 |
2000年 | 149篇 |
1999年 | 151篇 |
1998年 | 88篇 |
1997年 | 81篇 |
1996年 | 66篇 |
1995年 | 54篇 |
1994年 | 47篇 |
1993年 | 33篇 |
1992年 | 55篇 |
1991年 | 62篇 |
1990年 | 34篇 |
1989年 | 42篇 |
1988年 | 31篇 |
1987年 | 34篇 |
1986年 | 27篇 |
1985年 | 24篇 |
1984年 | 17篇 |
1983年 | 15篇 |
1982年 | 13篇 |
1981年 | 28篇 |
1980年 | 13篇 |
1979年 | 9篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1972年 | 5篇 |
1969年 | 5篇 |
Methods: The purpose of this study was to examine the degree to which several personal factors and school characteristics affect and explain students’ self-determination. A total of 232 students with intellectual disability from Spain participated. Their self-determination level was assessed by the ARC-INICO Scale.
Results: Students with moderate levels of intellectual disability obtained significantly lower scores on self-determination than their peers with mild intellectual disability. There were significant differences in relation to the level of support needs and their experience with transition programs. The level of support needs was a significant predictor.
Conclusion: These findings contribute to current research in this field and practical implications were discussed. 相似文献
Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献